MERCK
Merck’s Consumer Health division today hosted a top level debate on key future aspects of the OTC sector, at the Science Museum, London, UK. Featuring contributions from leading analysts, professional representatives and patient groups, the event combined the experience and views of Merck Consumer Health’s senior management team with external perspectives on the major pressures and influences facing the industry.
Commenting on today’s event and the publication of the results earlier this month Uta Kemmerich-Keil, Chief Executive Officer and President of Consumer Health, said: “Today’s debate is an important milestone for Merck’s Consumer Health division, as we become increasingly important players in the OTC sector. We hope that by bringing together leading stakeholders from the worlds of business, pharmacy and patient organizations, more clarity will emerge about the key pressures and opportunities that lie ahead for our sector. In light of our positive business results in Q3 and throughout the entire year, these influences are ever more important for mapping out a successful path ahead for our company and for the sector.”
Major challenges, major opportunities
A
dynamic business environment
As a sector, consumer health
has seen significant transactional activity in the last year, with
mergers and acquisitions influencing market share. For Merck’s Consumer
Health division, change and growth in operations has been driven by the
incorporation of new brands, transferred from Merck Serono. This has
helped drive a shift towards greater revenues from emerging markets. The
division’s strategy has successfully rested on the ‘3x3’ principle – a
focus on at least 3 leading consumer brands and a minimum market share
of 3% per key market.
Debate on the business environment at today’s event looked at the implications of such strategic approaches for consumers – and how likely it is that major change will be seen in the years ahead.
Increasing importance of healthcare professionals
As
a company founded on the principles of pharmacy, Merck has always
believed in the central role of the healthcare professional in providing
advice and guidance to consumers and patients on their choices. During
today’s event, delegates discussed the changing role of pharmacists in
providing advice and support to the community.
Commenting on this trend, President of the Royal Pharmaceutical Society and guest speaker Mr Ash Soni said: “Pharmacists are often the first port of call for those concerned about their health and can provide invaluable advice and support in an accessible setting. For the patient this provides assurance and a trusted source of information. For consumer health companies, pharmacists are a vital link between them and their customers – dispensing advice that patients rely on.”
Empowered and active consumers
Whether
evolutionary or revolutionary, the changing role of consumer behavior is
influencing the OTC sector as well. With patients increasingly willing
to navigate their own health journey, the demand for information and
choice has never been so high.
Dr Ian Banks, President of the European Men’s Health Forum and a guest panelist at the debate, stated that: “Many people are interested in proactively maintaining their own health – a trend which can only improve outcomes and wellbeing. However, many do not access health services at all, and it is these hard to reach groups which are most in need of pharmacy and primary care services. Striking a balance between health awareness and creating unnecessary demand is one of the key challenges facing the sector.”
Innovating into a leadership position
For the Consumer
Health division at Merck, 2014 has seen the launch of new product
innovations built on feedback from consumers. This has helped the
company gain market share in a highly competitive environment, driven by
the increasing importance of consumer trends and demands.
A notable example was the launch of Seven Seas Perfect7 – a product specifically tailored to help meet the needs of women and men in their advanced adulthood stage. The two Perfect7 offerings – one specifically for women and one for men – combine natural sources of marine oils rich in Omega-3 with key vitamins and minerals.
This innovation was driven by in-depth consumer insights generated through extensive consumer research activities which guided both R&D and Marketing to address the immediate consumer desire of staying and feeling “younger for longer”. And it is an insightful example of the new consumer-focused innovation approach at Merck’s Consumer Health division.
Leading discussion through financial success
Merck’s
Consumer Health division is playing an increasingly active role in the
sector, not just through facilitating debate on its future, but through
continued financial success based on the relentless focus on key
strategic brands and new product innovations.
In the third quarter of 2014, the division reported sound organic growth of 1.4% versus a very strong Q3 2013, totaling 5% year to date growth. Total sales stand at € 569.1 million year to date, versus € 561.8 million for the same time in 2013. Sales for the quarter stand at € 204.1 million, driven by strong growth particularly in emerging markets such as Brazil, Venezuela, Malaysia, Indonesia and South Africa.
Amongst Merck’s strategic brands, significant growth was experienced on Femibion, Seven Seas and Neurobion. The third quarter of 2014 also reported EBITDA pre one-time items of € 48.6 million, down 16.5% on last year’s very strong third quarter.
Notes for editors
- The top level debate entitled “Trends, challenges and opportunities in consumer health: evolution or revolution” took place at the Science Museum in London, United Kingdom, November 28, 2014. Further information, including photos and video are available here .
- Merck on Facebook , Twitter , LinkedIn
- Merck photos and video footage
Consumer Health Division of Merck
Brands of the Consumer
Health division, such as Neurobion®
, Bion®
, Nasivin®
,
Seven Seas®
, Dolo-Neurobion®
, and Femibion®
are innovative leaders in key markets, backed by science and trusted by
consumers worldwide. The division Consumer Health with its around 2,000
employees is active in more than 40 markets world-wide. Since 2014, the
portfolio comprises of brands with annual total sales of over
$ 1 billion. Consumer Health is a division of the Merck Group with
global headquarters in Darmstadt, Germany.
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors. With its four divisions With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as Merck KGaA, Darmstadt, Germany.
Contact:
Merck
Lars Atorf
Phone +49 6151 856-3114
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
IFF Completes Divestiture of Pharma Solutions Business Unit1.5.2025 08:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has successfully completed the previously announced divestiture of its Pharma Solutions business unit to Roquette. “The completion of our Pharma Solutions divestiture represents a significant milestone for IFF as we delivered our targeted net debt to credit-adjusted EBITDA of below 3.0x,” said Erik Fyrwald, IFF CEO. “This is an important step as it allows us to focus on our core strategy – capitalizing on the exciting growth opportunities within our key businesses – as we maximize long-term value for our shareholders. We’d like to thank our Pharma Solutions colleagues for their unwavering commitment and their dedication to exceptional customer service. We wish them continued success as they find a new home with Roquette.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that
More Impact, Together: Varian and Siemens Healthineers Portfolios Highlight More Impact, Innovations and More Breakthroughs Throughout Cancer Care Journey at ESTRO 20251.5.2025 08:00:00 CEST | Press release
Varian, a Siemens Healthineers company, will showcase an integrated portfolio designed to streamline workflows, and aiming to enhance patient experience and improve patient outcomes from screening to survivorship at the 2025 European Society for Radiotherapy and Oncology (ESTRO) annual meeting, May 2-6, in Vienna, Austria. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250430039992/en/ At Varian, a Siemens Healthineers company, we envision a world without fear of cancer. For more than 75 years, Varian has developed, built, and delivered innovative technologies and solutions that help care providers around the globe treat millions of patients each year. Today, as a Siemens Healthineers company, we support every step of the cancer care journey – from screening to survivorship. From advanced imaging and radiation therapy to comprehensive software and services, to interventional radiology, we are harnessing the power of our pers
REI Super Selects SS&C For Superannuation Administration1.5.2025 05:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that REI Super (“REI”), the superannuation fund for Australia’s real estate industry, has signed a long-term agreement to partner with SS&C. REI selected SS&C to serve as the fund’s administrator following a competitive tender process. SS&C Global Investor & Distribution Solutions (GIDS) will provide REI with superannuation administration services and streamlined operations support to its 24,000 members across Australia. REI will benefit from SS&C’s local administration expertise, supported by its global investment in digital service channels, automation and artificial intelligence to enhance the member experience. “As one of Australia’s longest-standing superannuation funds, our focus has always been on serving our members,” said Jarrod Coysh, CEO of REI Super. “SS&C’s extensive track record in fund administration and innovative technology make them the ideal operations partner to help us best meet our members’ needs.” “W
Svante and Mercer International Advance Carbon Capture Project at Alberta Pulp Mill1.5.2025 03:25:00 CEST | Press release
Svante Technologies Inc. (Svante), a leader in carbon capture and removal technology, today announced that its joint carbon capture and storage project with Mercer International Inc. (Mercer) has advanced to the Front-end Engineering and Design Phase 2 (FEL-2). Also known as Pre-FEED, this phase involves engineering, cost estimation, and risk analysis to evaluate the project's commercial viability. Mercer is a global producer of sustainably sourced forest products, including pulp, lumber, mass timber, biomass-based green energy, and bioextractives. The carbon capture project targets biogenic CO2 emissions from Mercer’s Peace River pulp mill, where the biomass (fibre) is sourced from sustainably managed forests. Advancing to the Pre-FEED stage will support further development of the integrated design, cost estimates, and risk assessments—key steps toward a final investment decision and potential implementation. This milestone reflects the growing momentum for carbon capture solutions wi
Andersen Global udvider sin europæiske værdiansættelseskapacitet gennem samarbejde med Value & Risk Valuation Services1.5.2025 03:03:00 CEST | Pressemeddelelse
Andersen Global fortsætter med at styrke sin værdiansættelseskapacitet gennem en samarbejdsaftale med Value & Risk Valuation Services, et fremtrædende europæisk værdiansættelsesfirma med hovedsæde i Tyskland og kontorer i Luxembourg og Østrig. Value & Risk Valuation Services blev grundlagt i 1996 og er et ledelsesejet firma, der har specialiseret sig i værdiansættelse af finansielle aktiver på tværs af forskellige aktivklasser og med varierende kompleksitet. Firmaet leverer også supplerende tjenester, herunder uafhængig prisverifikation (IPV), risikoanalyse og analyse af transaktionsomkostninger. Siden 2009 har virksomheden været ledet af Gil Bender, som er dedikeret til at levere kundecentrerede værdiansættelsesløsninger af høj kvalitet. Som en af de få europæiske udbydere, der tilbyder eksterne værdiansættelsestjenester i overensstemmelse med det europæiske direktiv om forvaltere af alternative investeringsfonde (AIFMD), opretholder Value & Risk de højeste industristandarder for over
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum